Literature DB >> 35554920

Biorisk Management for SARS-CoV-2 Research in a Biosafety Level-3 Core Facility.

Tessy Joseph1, Sabai Phyu2,3, Su Yun Se-Thoe4, Justin Jang Hann Chu5,6,7,8.   

Abstract

The emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents hazards to researchers and other laboratory personnel in research settings where the live virus is stored and handled. The Biosafety Level-3 (BSL-3) Core Facility (CF) at Yong Loo Lin School of Medicine in National University of Singapore (NUS Medicine) has implemented a biorisk management (BRM) system to ensure that biorisk to employees, the public, or the environment are consistently minimized to an acceptable level while working with SARS-CoV-2. This chapter summarizes how a BRM system can be implemented in academic institutions based on international standards in the context of existing local legislations/regulations and institutional policies/guidelines to minimize the risk of laboratory-acquired infections and deliberate misuse of the newly emerged virus, SARS-CoV-2 in BSL-3 laboratories. The BRM programs prioritize performing risk assessments prior to implementation of work processes and reassessing the risk portfolio of the facilities from time to time, determining root causes and prevention of recurrences. Focusing on awareness-raising and educating the laboratory users in biosafety and biosecurity, and identifying opportunities for improvement are the other key factors for a sustainable and successful BRM system in the NUS Medicine BSL-3 CF.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  BSL-3; Biorisk management; Biosafety; Biosecurity; COVID-19; ISO 35001:2019; Risk assessment; SARS-CoV-2

Mesh:

Year:  2022        PMID: 35554920     DOI: 10.1007/978-1-0716-2111-0_24

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  1 in total

Review 1.  Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea.

Authors:  Ki Ho Hong; Sang Won Lee; Taek Soo Kim; Hee Jae Huh; Jaehyeon Lee; So Yeon Kim; Jae Sun Park; Gab Jeong Kim; Heungsup Sung; Kyoung Ho Roh; Jae Seok Kim; Hyun Soo Kim; Seung Tae Lee; Moon Woo Seong; Namhee Ryoo; Hyukmin Lee; Kye Chul Kwon; Cheon Kwon Yoo
Journal:  Ann Lab Med       Date:  2020-09       Impact factor: 3.464

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.